CHA
CODX

Carmichael Hill & Associates’s Co-Diagnostics CODX Stock Holding History

Carmichael Hill & Associates’s Portfolio CODX Stock Details CODX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-1
Closed -$1K – 716
2020
Q2 		$1K Buy
+1
New +$456 ﹤0.01% 652

Other funds holding CODX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
IA
IFG Advisory Atlanta, Georgia $34.9M AUM 20.48% 1-Year Est. Return

Carmichael Hill & Associates's CODX Position: Q3 2020 in Review

Carmichael Hill & Associates sold out of Co-Diagnostics (CODX) in Q3 2020, closing a stake of 1 share — an estimated $1K sold.

Carmichael Hill & Associates first reported a position in CODX in Q2 2020 and held it in 1 quarter. The position peaked at $1K in Q2 2020. 81 funds tracked by Wall St. Rank hold CODX as of Q3 2020.

  • Carmichael Hill & Associates reported no remaining Co-Diagnostics position as of Q3 2020 after selling out during the quarter.
  • Carmichael Hill & Associates sold 1 Co-Diagnostics share in Q3 2020, an estimated $1K.
  • Carmichael Hill & Associates first reported a position in Co-Diagnostics in Q2 2020 and held it in 1 quarter.
  • Carmichael Hill & Associates's Co-Diagnostics position peaked at $1K in Q2 2020.
  • 81 funds tracked by Wall St. Rank held Co-Diagnostics as of Q3 2020.

Based on Carmichael Hill & Associates's 13F filing for Q3 2020, filed 12 Nov 2020.